Argenx To Acquire Forte Biosciences For $77 Per Share Cash, Valuing Deal At ~$2.2B, Adding CD122-Targeting FB102 With Vitiligo And Celiac Data

Loading news article.

Argenx To Acquire Forte Biosciences For $77 Per Share Cash, Valuing Deal At ~$2.2B, Adding CD122-Targeting FB102 With Vitiligo And Celiac Data | WAPE

Article summary